Literature DB >> 22136755

Recalcitrance of bacterial vaginosis among herpes-simplex-virus-type-2-seropositive women.

Kevin A Stoner1, Seth D Reighard, Rodolfo D Vicetti Miguel, Douglas Landsittel, Lisa A Cosentino, Jeffrey A Kant, Thomas L Cherpes.   

Abstract

AIM: The multifactorial etiology of bacterial vaginosis (BV) impedes development of effective treatment and prevention strategies. Herein, we evaluated the effects of herpes simplex virus type 2 (HSV-2), a suspected BV risk factor, on vaginal flora composition.
MATERIALS AND METHODS: Correlations between HSV-2 infection and BV were prospectively explored among 12 HSV-2-seropositive women with asymptomatic BV who were asked to collect daily vaginal swab specimens for Gram stain analysis of vaginal flora and determination of HSV-2 shedding frequencies during the 1month before and after metronidazole therapy.
RESULTS: Unlike prior longitudinal studies that reported rapid fluctuations in vaginal flora composition and frequent episodes of spontaneously resolving BV, we found that 99.4% (310/312) of vaginal smears collected before initiation of metronidazole were consistent with a diagnosis of BV. Effectiveness of metronidazole therapy was also much lower than previously reported in studies not restricting enrollment to HSV-2-seropositive women; we observed a BV recurrence rate of 89% in the first month after completion of therapy while the median time to this recurrence occurred only 14days after treatment.
CONCLUSIONS: Our study demonstrates BV recalcitrance among HSV-2-infected women and provides additional evidence for a linkage between this chronic viral infection and abnormal vaginal flora. Additional work will be needed to define mechanisms responsible for this correlation and to determine if vaginal flora health of HSV-2-infected women is improved by medications that suppress HSV-2 shedding.
© 2011 The Authors. Journal of Obstetrics and Gynaecology Research © 2011 Japan Society of Obstetrics and Gynecology.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22136755      PMCID: PMC3253171          DOI: 10.1111/j.1447-0756.2011.01697.x

Source DB:  PubMed          Journal:  J Obstet Gynaecol Res        ISSN: 1341-8076            Impact factor:   1.730


  30 in total

1.  Efficacy of clindamycin vaginal cream versus oral metronidazole in the treatment of bacterial vaginosis.

Authors:  F Fischbach; E E Petersen; E R Weissenbacher; J Martius; J Hosmann; H Mayer
Journal:  Obstet Gynecol       Date:  1993-09       Impact factor: 7.661

2.  Comparison of two different regimens of metronidazole in the treatment of non-specific vaginitis.

Authors:  B Hagström; J Lindstedt
Journal:  Scand J Infect Dis Suppl       Date:  1983

3.  Vaginal lactobacilli, microbial flora, and risk of human immunodeficiency virus type 1 and sexually transmitted disease acquisition.

Authors:  H L Martin; B A Richardson; P M Nyange; L Lavreys; S L Hillier; B Chohan; K Mandaliya; J O Ndinya-Achola; J Bwayo; J Kreiss
Journal:  J Infect Dis       Date:  1999-12       Impact factor: 5.226

4.  Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation.

Authors:  R P Nugent; M A Krohn; S L Hillier
Journal:  J Clin Microbiol       Date:  1991-02       Impact factor: 5.948

5.  Rapid fluctuation of the vaginal microbiota measured by Gram stain analysis.

Authors:  Rebecca M Brotman; Jacques Ravel; Richard A Cone; Jonathan M Zenilman
Journal:  Sex Transm Infect       Date:  2010-08       Impact factor: 3.519

6.  Risk factors for infection with herpes simplex virus type 2: role of smoking, douching, uncircumcised males, and vaginal flora.

Authors:  Thomas L Cherpes; Leslie A Meyn; Marijane A Krohn; Sharon L Hillier
Journal:  Sex Transm Dis       Date:  2003-05       Impact factor: 2.830

7.  Anaerobic vaginosis (non-specific vaginitis): clinical, microbiological, and therapeutic findings.

Authors:  A L Blackwell; A R Fox; I Phillips; D Barlow
Journal:  Lancet       Date:  1983-12-17       Impact factor: 79.321

8.  Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations.

Authors:  R Amsel; P A Totten; C A Spiegel; K C Chen; D Eschenbach; K K Holmes
Journal:  Am J Med       Date:  1983-01       Impact factor: 4.965

9.  Clindamycin vaginal cream versus oral metronidazole in the treatment of bacterial vaginosis: a prospective double-blind clinical trial.

Authors:  F J Andres; R Parker; I Hosein; G I Benrubi
Journal:  South Med J       Date:  1992-11       Impact factor: 0.954

10.  Risk factors for prematurity and premature rupture of membranes: a prospective study of the vaginal flora in pregnancy.

Authors:  H Minkoff; A N Grunebaum; R H Schwarz; J Feldman; M Cummings; W Crombleholme; L Clark; G Pringle; W M McCormack
Journal:  Am J Obstet Gynecol       Date:  1984-12-15       Impact factor: 8.661

View more
  2 in total

1.  Serum vitamin D status and bacterial vaginosis prevalence and incidence in Zimbabwean women.

Authors:  Abigail N Turner; Patricia Carr Reese; Pai Lien Chen; Cynthia Kwok; Rebecca D Jackson; Mark A Klebanoff; Raina N Fichorova; Tsungai Chipato; Charles S Morrison
Journal:  Am J Obstet Gynecol       Date:  2016-03-02       Impact factor: 8.661

2.  Comparison of the vaginal microbial communities in women with recurrent genital HSV receiving acyclovir intravaginal rings.

Authors:  Luke K Ursell; Manjula Gunawardana; Simon Chang; Madeline Mullen; John A Moss; Betsy C Herold; Marla J Keller; Daniel McDonald; Antonio González; Rob Knight; Marc M Baum
Journal:  Antiviral Res       Date:  2013-12-19       Impact factor: 5.970

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.